Tempus AI (TEM) Stock Skyrockets on AI Healthcare Breakthroughs – What Investors Need to Know
Tempus AI shares closed at a record $102.31 on October 8, 2025, nearly tripling year-to-date after FDA clearance for new AI diagnostics and the $81.3 million acquisition of Paige. Q2 revenue surged 89.6% to $314.6 million, with net losses narrowing and positive adjusted EBITDA forecast for 2025. Market cap stands near $17 billion.